文献(501～600)

501. Anselmino M, Matta M, D’Ascenzo F, et al. Catheter ablation of atrial fibrillation in patients with left ventricular systolic dysfunction: a

systematic review and meta-analysis. Circ Arrhythm Electrophysiol 2014; 7: 1011-1018. PMID: 25262686

502. Gopinathannair R, Etheridge SP, Marchlinski FE, et al. Arrhythmia- Induced Cardiomyopathies: Mechanisms, Recognition, and

Management. J Am Coll Cardiol 2015; 66: 1714-1728. PMID: 26449143

503. Lip GY, Frison L, Halperin JL, et al. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary

stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 2010; 41: 2731-2738. PMID: 20966417

504. Camm AJ, Kirchhof P, Lip GY, et al. European Heart Rhythm Association. Guidelines for the management of atrial fibrillation: the Task

Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429. PMID:

20802247

505. Giugliano RP, Ruff CT, Braunwald E, et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation.

N Engl J Med 2013; 369: 2093-2104. PMID: 24251359

506. Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with

atrial fibrillation. N Engl J Med 2011; 365: 981-992. PMID: 21870978

507. Houston DS, Zarychanski R. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 2671; author reply

2674-2675. PMID: 20042760

508. Pearson S, Troughton R, Richards AM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 2334-2335;

author reply 2335. PMID: 22168653

509. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients

with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-962. PMID: 24315724

510. Xiong Q, Lau YC, Senoo K, et al. Non-vitamin K antagonist oral anticoagulants(NOACs) in patients with concomitant atrial fibrillation

and heart failure: a systemic review and meta-analysis of randomized trials. Eur J Heart Fail 2015; 17: 1192-1200. PMID: 26335355

511. Eikelboom JW, Connolly SJ, Brueckmann M, et al. RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical

heart valves. N Engl J Med 2013; 369: 1206-1214. PMID: 23991661

512. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with

atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093- 1100. PMID: 20299623

513. Klein AL, Grimm RA, Murray RD, et al. Assessment of Cardioversion Using Transesophageal Echocardiography Investigators. Use of

transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001; 344: 1411-1420. PMID:

11346805

514. Dewilde WJ, Oirbans T, Verheugt FW, et al. WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral

anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013;

381: 1107-1115. PMID: 23415013

515. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with

EACTS. Eur Heart J 2016; 37: 2893-2962. PMID: 27567408

516. Cannon CP, Bhatt DL, Oldgren J, et al. RE-DUAL PCI Steering Committee and Investigators. Dual Antithrombotic Therapy with

Dabigatran after PCI in Atrial Fibrillation. N Engl J Med 2017; 377: 1513-1524. PMID: 28844193

517. Irani WN, Grayburn PA, Afridi I. Prevalence of thrombus, spontaneous echo contrast, and atrial stunning in patients undergoing

cardioversion of atrial flutter. A prospective study using transesophageal echocardiography. Circulation 1997; 95: 962-966. PMID: 9054758

518. Shiga T, Kasanuki H. Drug therapy for ventricular tachyarrhythmia in heart failure. Circ J 2007; 71 Suppl: A90-A96. PMID: 17587746

519. Katoh T, Mitamura H, Matsuda N, et al. Emergency treatment with nifekalant, a novel class III anti-arrhythmic agent, for life-threatening

refractory ventricular tachyarrhythmias: post-marketing special investigation. Circ J 2005; 69: 1237-1243. PMID: 16195624

520. Itoh H, Crotti L, Aiba T, et al. The genetics underlying acquired long QT syndrome: impact for genetic screening. Eur Heart J 2016; 37:

1456-1464. PMID: 26715165

521. Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation 1988; 77: 392-397. PMID:

3338130

522. Carbucicchio C, Santamaria M, Trevisi N, et al. Catheter ablation for the treatment of electrical storm in patients with implantable

cardioverter- defibrillators: short- and long-term outcomes in a prospective single-center study. Circulation 2008; 117: 462-469. PMID:

18172038

523. Hayashi M, Miyauchi Y, Murata H, et al. Urgent catheter ablation for sustained ventricular tachyarrhythmias in patients with acute heart

failure decompensation. Europace 2014; 16: 92-100. PMID: 23858022

524. Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, et al. JCARE-GENERAL Investigators. Characteristics and outcomes of patients with

heart failure in general practices and hospitals. Circ J 2007; 71: 449- 454. PMID: 17384441

525. Sakata Y, Shimokawa H. Epidemiology of heart failure in Asia. Circ J 2013; 77: 2209-2217. PMID: 23955345

526. Kajimoto K, Sato N, Takano T. investigators of the Acute Decompensated Heart Failure Syndromes (ATTEND) registry. Relation of left

ventricular ejection fraction and clinical features or co-morbidities to outcomes among patients hospitalized for acute heart failure

syndromes. Am J Cardiol 2015; 115: 334-340. PMID: 25476557

527. Shiba N, Watanabe J, Shinozaki T, et al. Poor prognosis of Japanese patients with chronic heart failure following myocardial infarction--

comparison with nonischemic cardiomyopathy. Circ J 2005; 69:143-149. PMID: 15671603

528. Kajimoto K, Minami Y, Sato N, et al. Investigators of the Acute Decompensated Heart Failure Syndromes (ATTEND) Registry. Etiology

of Heart Failure and Outcomes in Patients Hospitalized for Acute Decompensated Heart Failure With Preserved or Reduced Ejection

Fraction. Am J Cardiol 2016; 118: 1881-1887. PMID: 27720439

529. Hochman JS, Sleeper LA, Webb JG, et al. SHOCK Investigators. Early revascularization and long-term survival in cardiogenic shock

complicating acute myocardial infarction. JAMA 2006; 295: 2511- 2515. PMID: 16757723

530. Matsubara T, Minatoguchi S, Matsuo H, et al. Three minute, but not one minute, ischemia and nicorandil have a preconditioning effect in

patients with coronary artery disease. J Am Coll Cardiol 2000; 35: 345-351. PMID: 10676679

531. Iwakura K, Ito H, Okamura A, et al. Nicorandil treatment in patients with acute myocardial infarction: a meta-analysis. Circ J 2009; 73:

925-931. PMID: 19325192

532. Asakura M, Kitakaze M. Cardioprotection in the clinical setting-lessons from J-WIND studies. Cardiovasc Drugs Ther 2010; 24: 289-

295. PMID: 20689987

533. Kitakaze M, Asakura M, Kim J, et al. J-WIND investigators. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion

treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 2007; 370: 1483-1493. PMID: 17964349　Erratumin:

Lancet. 2008; 370: 2102.

534. Ricci R, Coletta C, Ceci V, et al. RIMA Researchers. Effect of early treatment with captopril and metoprolol singly and together on

postinfarction left ventricular remodeling. Am Heart J 2001; 142: E5. PMID: 11579369

535. Califf RM, Lokhnygina Y, Velazquez EJ, et al. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction

with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial). Am J Cardiol 2009; 104:

151-157. PMID: 19576338

536. 日本循環器学会．循環器病の診断と治療に関するガイドライン．急性心筋梗塞（ST上昇型）の診療に関するガイドライン．Circ J

2008；72 Suppl IV: 1348-1442.

537. Figueras J, Calvo F, Cortadellas J, et al. Comparison of patients with and without papillary muscle rupture during acute myocardial

infarction. Am J Cardiol 1997; 80: 625-627. PMID: 9294995

538. Lemery R, Smith HC, Giuliani ER, et al. Prognosis in rupture of the ventricular septum after acute myocardial infarction and role of early

surgical intervention. Am J Cardiol 1992; 70: 147-151. PMID:1626498

539. 泰江弘文．心不全と神経体液性因子．医学書院 1999: 1-11.

540. 木之下正彦．心不全と循環ペプチド．Cardiac Practice 1999; 10:259-263.

541. Fearon WF, Shah M, Ng M, et al. Predictive value of the index of microcirculatory resistance in patients with ST-segment elevation

myocardial infarction. J Am Coll Cardiol 2008; 51: 560-565. PMID: 18237685

542. Lorell BH, Isoyama S, Grice WN, et al. Effects of ouabain and isoproterenol on left ventricular diastolic function during low-flow ischemia

in isolated, blood-perfused rabbit hearts. Circ Res 1988; 63: 457-467. PMID: 3396161

543. Isoyama S, Apstein CS, Wexler LF, et al. Acute decrease in left ventricular diastolic chamber distensibility during simulated angina in

isolated hearts. Circ Res 1987; 61: 925-933. PMID: 3677344

544. Slezak J, Tribulova N, Okruhlicova L, et al. Hibernating myocardium: pathophysiology, diagnosis, and treatment. Can J Physiol Pharmacol

2009; 87: 252-265. PMID: 19370079

545. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor

dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996; 94:

258-265. PMID: 8759064

546. Kitakaze M, Asanuma H, Funaya H, et al. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers synergistically

increase coronary blood flow in canine ischemic myocardium: role of bradykinin. J Am Coll Cardiol 2002; 40: 162-166. PMID: 12103271

547. Japanese beta-Blockers and Calcium Antagonists Myocardial Infarction (JBCMI) Investigators. Comparison of the effects of beta blockers

and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. Am J Cardiol 2004; 93:

969-973. PMID: 15081437

548. Elkayam U, Johnson JV, Shotan A, et al. Double-blind, placebo-controlled study to evaluate the effect of organic nitrates in patients with

chronic heart failure treated with angiotensin-converting enzyme inhibition. Circulation 1999; 99: 2652-2657. PMID: 10338458

549. Yui Y, Sumiyoshi T, Kodama K, et al. Japan Multicenter Investigation for Cardiovascular Diseases-B Study Group. Comparison of

nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan

Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res 2004; 27: 181-191. PMID: 15080377

550. Elefteriades JA, Tolis G, Levi E, et al. Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival with improved

ejection fraction and functional state. J Am Coll Cardiol 1993; 22: 1411-1417. PMID: 8227799

551. Baker DW, Jones R, Hodges J, et al. Management of heart failure. III. The role of revascularization in the treatment of patients with

moderate or severe left ventricular systolic dysfunction. JAMA 1994; 272: 1528-1534. PMID: 7966846

552. Passamani E, Davis KB, Gillespie MJ, et al. A randomized trial of coronary artery bypass surgery. Survival of patients with a low ejection

fraction. N Engl J Med 1985; 312: 1665-1671. PMID: 3873614

553. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina:

a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on

Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 1999; 33: 2092-2197. PMID: 10362225

554. Marui A, Kimura T, Nishiwaki N, et al. CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators. Three-year outcomes after percutaneous

coronary intervention and coronary artery bypass grafting in patients with heart failure: from the CREDO-Kyoto percutaneous

coronary intervention/coronary artery bypass graft registry cohort-2†. Eur J Cardiothorac Surg 2015; 47: 316-321; discussion 321. PMID:

24662243

555. 日本循環器学会．不整脈の非薬物治療ガイドライン（2011年改訂版）．http://www.j-circ.or.jp/guideline/pdf/JCS2011_okumura_h.pdf

556. 日本循環器学会．弁膜疾患の非薬物治療に関するガイドライン（2012年改訂版）．

http://www.j-circ.or.jp/guideline/pdf/JCS2012_ookita_h.pdf

557. Koelling TM, Aaronson KD, Cody RJ, et al. Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left

ventricular systolic dysfunction. Am Heart J 2002; 144: 524-529. PMID: 12228791

558. Trichon BH, Felker GM, Shaw LK, et al. Relation of frequency and severity of mitral regurgitation to survival among patients with left

ventricular systolic dysfunction and heart failure. Am J Cardiol 2003; 91: 538-543. PMID: 12615256

559. Grigioni F, Enriquez-Sarano M, Zehr KJ, et al. Ischemic mitral regurgitation: long-term outcome and prognostic implications with

quantitative Doppler assessment. Circulation 2001; 103: 1759-1764. PMID:11282907

560. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive

summary: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. J Am

Coll Cardiol 2014; 63: 2438-2488. PMID: 24603192

561. Vahanian A, Alfieri O, Andreotti F, et al. Joint Task Force on the Management of Valvular Heart Disease of the European Society of

Cardiology (ESC). Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012; 33: 2451-2496. PMID:

22922415

562. Michler RE, Smith PK, Parides MK, et al. CTSN. Two-Year Outcomes of Surgical Treatment of Moderate Ischemic Mitral Regurgitation.

N Engl J Med 2016; 374: 1932-1941. PMID: 27040451

563. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of

Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical

Practice Guidelines. J Am Coll Cardiol 2017; 70: 252-289. PMID: 28315732

564. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557-1562. PMID:

8622246

565. Lip GY, Skjøth F, Overvad K, et al. Blood pressure and prognosis in patients with incident heart failure: the Diet, Cancer and Health (DCH)

cohort study. Clin Res Cardiol 2015; 104: 1088-1096. PMID: 26111867

566. Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary

artery disease be dangerous? Ann Intern Med 2006; 144: 884- 893. PMID: 16785477

567. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients

with diabetes and coronary artery disease. JAMA 2010; 304: 61-68. PMID: 20606150

568. Bozkurt B, Aguilar D, Deswal A, et al. Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus,

Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association.

Circulation 2016; 134: e535-e578. PMID: 27799274

569. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with

heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273: 1450-1456. PMID: 7654275

570. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled- release metoprolol on total mortality, hospitalizations, and

well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF).

MERIT-HF Study Group. JAMA 2000; 283: 1295-1302. PMID: 10714728

571. Packer M, Fowler MB, Roecker EB, et al. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect

of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative

survival (COPERNICUS) study. Circulation 2002; 106: 2194- 2199. PMID: 12390947

572. McMurray JJ, Packer M, Desai AS, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril

in heart failure. N Engl J Med 2014; 371: 993-1004. PMID: 25176015

573. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An

Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/

American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2016;

134: e282-e293. PMID: 27208050

574. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone:

the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000; 283: 1967-1975. PMID:

10789664

575. Senni M, Paulus WJ, Gavazzi A, et al. New strategies for heart failure with preserved ejection fraction: the importance of targeted

therapies for heart failure phenotypes. Eur Heart J 2014; 35: 2797-2815. PMID: 25104786

576. Ferrari R, Böhm M, Cleland JG, et al. Heart failure with preserved ejection fraction: uncertainties and dilemmas. Eur J Heart Fail 2015;

17: 665-671. PMID: 26079097

577. Udelson JE. Heart failure with preserved ejection fraction. Circulation 2011; 124: e540-e543. PMID: 22105201

578. Faris RF, Flather M, Purcell H, et al. Diuretics for heart failure. Cochrane Database Syst Rev 2012: CD003838. PMID: 22336795

579. Solomon SD, Zile M, Pieske B, et al. Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved

ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved

ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012; 380: 1387-1395. PMID: 22932717

580. Choy CK, Rodgers JE, Nappi JM, et al. Type 2 diabetes mellitus and heart failure. Pharmacotherapy 2008; 28: 170-192. PMID: 18225964

581. Sato N, Kajimoto K, Asai K, et al. ATTEND Investigators. Acute decompensated heart failure syndromes (ATTEND) registry. A prospective

observational multicenter cohort study: rationale, design, and preliminary data. Am Heart J 2010; 159: 949-955.e1. PMID:20569705

582. Yancy CW, Lopatin M, Stevenson LW, et al. ADHERE Scientific Advisory Committee and Investigators. Clinical presentation,

management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function:

a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006; 47: 76-84. PMID:

16386668

583. Gheorghiade M, Abraham WT, Albert NM, et al. OPTIMIZE-HF Investigators and Coordinators. Systolic blood pressure at admission,

clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006; 296: 2217-2226. PMID: 17090768

584. Boyer JK, Thanigaraj S, Schechtman KB, et al. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients

with diabetes mellitus. Am J Cardiol 2004; 93: 870-875. PMID: 15050491

585. From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a

population-based study. J Am Coll Cardiol 2010; 55: 300-305. PMID: 20117433

586. Malmberg K, Yusuf S, Gerstein HC, et al. Impact of diabetes on longterm prognosis in patients with unstable angina and non-Q-wave

myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000; 102:

1014-1019. PMID: 10961966

587. Ingelsson E, Sundström J, Arnlöv J, et al. Insulin resistance and risk of congestive heart failure. JAMA 2005; 294: 334-341. PMID:

16030278

588. Bahrami H, Bluemke DA, Kronmal R, et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity:

the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 2008; 51: 1775-1783. PMID: 18452784

589. Miura M, Sakata Y, Miyata S, et al. CHART-2 Investigators. Prognostic Impact of Diabetes Mellitus in Chronic Heart Failure According to

Presence of Ischemic Heart Disease - With Special Reference to Nephropathy. Circ J 2015; 79: 1764-1772. PMID: 26004750

590. Haas SJ, Vos T, Gilbert RE, et al. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes

mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 2003; 146: 848-853. PMID: 14597934

591. Deedwania PC, Giles TD, Klibaner M, et al. MERIT-HF Study Group. Efficacy, safety and tolerability of metoprolol CR/XL in patients

with diabetes and chronic heart failure: experiences from MER IT-HF. Am Heart J 2005; 149: 159-167. PMID: 15660048

592. Heart Failure Society Of America. Evaluation and management of patients with acute decompensated heart failure. J Card Fail 2006;

12: e86-e103. PMID: 16500576

593. Bakris GL, Fonseca V, Katholi RE, et al. GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2

diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292: 2227-2236. PMID: 15536109

594. Fernandez HM, Leipzig RM. Spironolactone in patients with heart failure. N Engl J Med 2000; 342: 132; author reply 133-134. PMID:

10636750

595. Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001; 103: 2668-

2673. PMID: 11390335

596. Aguilar D, Bozkurt B, Ramasubbu K, et al. Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am

Coll Cardiol 2009; 54: 422-428. PMID: 19628117

597. Connelly KA, Yan AT, Leiter LA, et al. Cardiovascular Implications of Hypoglycemia in Diabetes Mellitus. Circulation 2015; 132: 2345-

2350. PMID: 26667098

598. Guan Y, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal

salt absorption. Nat Med 2005; 11: 861-866. PMID: 16007095

599. Hernandez AV, Usmani A, Rajamanickam A, et al. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2

diabetes mellitus: a meta-analysis and meta-regression analysis of placebo- controlled randomized clinical trials. Am J Cardiovasc Drugs

2011; 11: 115-128. PMID: 21294599

600. Eurich DT, Majumdar SR, McAlister FA, et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart

failure. Diabetes Care 2005; 28: 2345-2351. PMID: 16186261